On April 7, 2025, Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibody therapeutics, announced that it has completed the acquisition of TigaTx, a Boston-based biotechnology company developing engineered immunoglobulin A (IgA) antibodies, to create the world’s leading pan-isotype cancer antibody company.

As a result of the combination of these two privately held companies, TigaTx becomes a wholly owned subsidiary of Epsilogen. Financial terms of the transaction have not been disclosed.

The Wilson Sonsini team advising TigaTx on the transaction included: 

Corporate
Mark Solakian
Jake D. Gatof
Tamara Labanowski
Aaron B. Gordon
Alex Stebbins

Tax
Derek E. Wallace

For more information, please refer to the press release and this news release.